• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Omitting sentinel lymph node biopsy in early breast cancer: too bold or the future?

作者信息

Zhao Jianli, Zhou Ziyue, Zhang Wei, Chen Kai

机构信息

Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.

Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.

出版信息

Transl Breast Cancer Res. 2025 Jul 23;6:27. doi: 10.21037/tbcr-25-14. eCollection 2025.

DOI:10.21037/tbcr-25-14
PMID:40756954
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12314679/
Abstract
摘要

相似文献

1
Omitting sentinel lymph node biopsy in early breast cancer: too bold or the future?早期乳腺癌省略前哨淋巴结活检：过于大胆还是未来趋势？
Transl Breast Cancer Res. 2025 Jul 23;6:27. doi: 10.21037/tbcr-25-14. eCollection 2025.
2
Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1-2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup-Sentinel-Mamma (INSEMA) Trial.保乳治疗背景下临床及超声检查腋窝淋巴结阴性的早期浸润性乳腺癌（c/iT1-2）的腋窝分期限制：国际乳腺癌前哨淋巴结研究组（INSEMA）试验启动后的初步结果
Geburtshilfe Frauenheilkd. 2017 Feb;77(2):149-157. doi: 10.1055/s-0042-122853.
3
Sentinel lymph node biopsy omission in early-stage breast cancer: current evidence and clinical practice.早期乳腺癌前哨淋巴结活检的遗漏：当前证据与临床实践
Front Oncol. 2025 Jun 19;15:1598730. doi: 10.3389/fonc.2025.1598730. eCollection 2025.
4
Deep learning to predict breast cancer sentinel lymph node status on INSEMA histological images.深度学习预测 INSEMA 组织学图像上的乳腺癌前哨淋巴结状态。
Eur J Cancer. 2023 Dec;195:113390. doi: 10.1016/j.ejca.2023.113390. Epub 2023 Oct 18.
5
Patient-reported outcomes for the Intergroup Sentinel Mamma study (INSEMA): A randomised trial with persistent impact of axillary surgery on arm and breast symptoms in patients with early breast cancer.乳腺癌国际协作组前哨淋巴结研究（INSEMA）的患者报告结局：一项关于早期乳腺癌患者腋窝手术对手臂和乳房症状有持续影响的随机试验。
EClinicalMedicine. 2022 Nov 25;55:101756. doi: 10.1016/j.eclinm.2022.101756. eCollection 2023 Jan.
6
Safety and Accuracy of Sentinel Lymph Node Biopsy Alone in Clinically Node-Positive Patients Undergoing Upfront Surgery for Invasive Breast Cancer: A Systematic Review.单独使用前哨淋巴结活检术在浸润性乳腺癌行 upfront 手术的临床阳性淋巴结患者中的安全性和准确性：一项系统评价。
Curr Oncol. 2023 Mar 7;30(3):3102-3110. doi: 10.3390/curroncol30030235.
7
Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial.前哨淋巴结活检与阴性超声腋窝淋巴结结果的小乳腺癌患者不进行腋窝手术的比较：SOUND 随机临床试验。
JAMA Oncol. 2023 Nov 1;9(11):1557-1564. doi: 10.1001/jamaoncol.2023.3759.
8
Local treatment of the axilla in early breast cancer: concepts from the national surgical adjuvant breast and bowel project B-04 to the planned intergroup sentinel mamma trial.早期乳腺癌腋窝的局部治疗：从国家外科辅助乳腺和肠道项目B-04到计划中的组间前哨乳腺试验的理念
Breast Care (Basel). 2014 May;9(2):87-95. doi: 10.1159/000360411.
9
Axillary treatment for operable primary breast cancer.可手术原发性乳腺癌的腋窝治疗
Cochrane Database Syst Rev. 2017 Jan 4;1(1):CD004561. doi: 10.1002/14651858.CD004561.pub3.
10
The efficacy and oncological safety of minimally invasive axillary procedures in patients with node-positive breast cancer receiving neoadjuvant chemotherapy: A network meta-regression and trial sequential analysis.接受新辅助化疗的淋巴结阳性乳腺癌患者微创腋窝手术的疗效及肿瘤学安全性：一项网状Meta回归和试验序贯分析
Eur J Surg Oncol. 2025 Jul;51(7):109689. doi: 10.1016/j.ejso.2025.109689. Epub 2025 Feb 20.

本文引用的文献

1
Axillary Surgery in Breast Cancer - Primary Results of the INSEMA Trial.乳腺癌腋窝手术——INSEMA试验的初步结果
N Engl J Med. 2025 Mar 13;392(11):1051-1064. doi: 10.1056/NEJMoa2412063. Epub 2024 Dec 12.
2
Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer: The LUMINA Study.保乳手术后省略腔面A型乳腺癌放疗：LUMINA研究
J Am Coll Surg. 2025 Mar 1;240(3):307-312. doi: 10.1097/XCS.0000000000001239. Epub 2025 Feb 14.
3
Diffusion-weighted imaging in addition to contrast-enhanced MRI in identifying complete response in HER2-positive breast cancer.
弥散加权成像联合对比增强 MRI 识别 HER2 阳性乳腺癌的完全缓解。
Eur Radiol. 2024 Dec;34(12):7994-8004. doi: 10.1007/s00330-024-10857-7. Epub 2024 Jul 5.
4
Use of ctDNA in early breast cancer: analytical validity and clinical potential.循环肿瘤DNA在早期乳腺癌中的应用：分析有效性和临床潜力。
NPJ Breast Cancer. 2024 Jun 19;10(1):50. doi: 10.1038/s41523-024-00653-3.
5
Ribociclib plus Endocrine Therapy in Early Breast Cancer.来曲唑联合内分泌治疗早期乳腺癌。
N Engl J Med. 2024 Mar 21;390(12):1080-1091. doi: 10.1056/NEJMoa2305488.
6
Quality assurance of radiation therapy after breast-conserving surgery among patients in the BOOG 2013-08 trial.保乳手术后 BOOG 2013-08 试验中患者的放射治疗质量保证。
Radiother Oncol. 2024 Feb;191:110069. doi: 10.1016/j.radonc.2023.110069. Epub 2023 Dec 21.
7
Diagnostic performance of contrast-enhanced ultrasound combined with shear wave elastography in differentiating benign from malignant breast lesions: a systematic review and meta-analysis.超声造影联合剪切波弹性成像在鉴别乳腺良恶性病变中的诊断性能：一项系统评价和荟萃分析
Gland Surg. 2023 Nov 24;12(11):1610-1623. doi: 10.21037/gs-23-333. Epub 2023 Oct 20.
8
Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA.保乳手术后临床和基因组低风险乳腺癌患者省略放疗：IDEA 的 5 年结果。
J Clin Oncol. 2024 Feb 1;42(4):390-398. doi: 10.1200/JCO.23.02270. Epub 2023 Dec 7.
9
Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial.前哨淋巴结活检与阴性超声腋窝淋巴结结果的小乳腺癌患者不进行腋窝手术的比较：SOUND 随机临床试验。
JAMA Oncol. 2023 Nov 1;9(11):1557-1564. doi: 10.1001/jamaoncol.2023.3759.
10
An Analysis of Clinical and Pathologic Features, RecurIndex Genomic Profiles, and Survival Outcomes in HER2-Low Breast Cancer.HER2 低表达乳腺癌的临床病理特征、RecurIndex 基因组特征分析及生存结局
Oncologist. 2023 Dec 11;28(12):e1160-e1169. doi: 10.1093/oncolo/oyad159.